



Inadvertent Error: Evaluation of Bevacizumab for the Treatment of Epidural Fibrosis by Immunohistochemical Staining for CD105 and Osteopontin

Ilhan YILMAZ¹, Uzay ERDOGAN², Osman TANRIVERDI², Omur GUNALDI², H. Utku ADILAY³, Muhammed OMEROGLU⁴, Canan TANIK⁵, Bekir TUGCU²

¹University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Neurosurgery, Istanbul, Turkey

²University of Health Sciences, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Neurosurgery and Psychiatry, Istanbul, Turkey

³Balikesir University, School of Medicine, Department of Neurosurgery, Balikesir, Turkey

⁴Toyotas State Hospital, Department of Neurosurgery, Sakarya, Turkey

⁵University of Health Sciences, Sisli Hamidiye Etfal Training and Research Hospital, Department of Pathology, Istanbul, Turkey

Corresponding author: Osman TANRIVERDI ✉ osmantanriverdi74@gmail.com

As the authors of the paper titled “*Evaluation of Bevacizumab for the Treatment of Epidural Fibrosis by Immunohistochemical Staining for CD105 and Osteopontin*” published in 2018, Volume 28(6), pp. 954–962, we have noticed after a retrospective review of this paper that **Figure 3A** is incorrect, namely, the picture of **Figure 3B**

is correct but not the caption (1). The information regarding **Figure 3A–B** was explained as it should be within the text, but, mistakenly, the wrong picture and caption were provided in **Figure 3A**, and the wrong caption was given for **Figure 3B**. The (*incorrect*) version of **Figure 3A–B** published in the paper was as follows:




Figure 3: Immunohistochemical staining for CD105. **A)** Grade III fibrosis in a control animal in group I. **B)** Grade I fibrosis in a bevacizumab-treated animal in group II (star, neural tissue; black arrow, dura; blue arrow, fibrosis).

Ilhan YILMAZ  : 0000-0001-5548-2228
Uzay ERDOGAN  : 0000-0001-8268-6306
Osman TANRIVERDI  : 0000-0002-4846-4213

Omur GUNALDI  : 0000-0001-5071-1319
H. Utku ADILAY  : 0000-0003-4867-244X
Muhammed OMEROGLU  : 0000-0001-7130-1802

Canan TANIK  : 0000-0003-2435-7533
Bekir TUGCU  : 0000-0003-0385-0054

The (correct) pictures and captions of **Figure 3A–B** should be as follows:




Figure 3: Immunohistochemical staining for CD105. **A)** Grade III fibrosis in a control animal in group I (star, neural tissue; blue arrow, fibrosis). **B)** Grade I fibrosis in a bevacizumab-treated animal in group II (star, neural tissue; black arrow, fibrosis).

The error relating to **Figure 3A–B** in the published version did not affect any statistical data or the study outcome.

As the authors of the article, we hereby amend this mistake and correct the figures and present them as they should be in order not to misinform our colleagues who will read our study.

■ REFERENCES

1. Yilmaz I, Erdogan U, Tanriverdi O, Gunaldi O, Adilay U, Omeroglu M, Tanik C, Tugcu B: Evaluation of bevacizumab for the treatment of epidural fibrosis by immunohistochemical staining for CD105 and osteopontin. *Turk Neurosurg* 28(6):954-962, 2018